People
The funds will be used to advance the firm’s precision oncology research efforts and pipeline, particularly those involving the creation of alteration-specific therapies.
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.
Hal Barron, the man who guided the reinvigoration of the pharmaceutical direction at GSK, is departing the company to be the CEO of Altos Labs.
The company’s co-Founder, President and CEO Dr. P. Peter Ghoroghchian, took time to discuss the company and the financing round with BioSpace.
Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world.
The problem Kinaset is trying to solve is that over time, patients receiving asthma therapies – typically inhaled corticosteroids plus bronchodilators – become steroid-refractory.
While many of these scams targeted the public at large, scammers also turned their sights to those sources that would naturally be on the spot as the result of demand.
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
Martin Shkreli and his former company, Vyera Pharmaceuticals, earned a 5,000% increase on the toxoplasmosis drug, Daraprim.
PRESS RELEASES